SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00586651
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of
CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with
Essential Thrombocytosis (ET).
Name: lestaurtinib
Description: 60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment durationType: Drug
lestaurtinib
Primary Outcomes
Measure: Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.
Time: 18 weeks +
Secondary Outcomes
Measure: - improvements in hemoglobin values, neutrophil count, and platelet count. - reduction in dose of hydroxyurea - reduction in splenic enlargement - rate of phlebotomy
Time: 18 weeks +
Purpose: Treatment
Single Group Assignment
There is one SNP
SNPs
1 V617F
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation. --- V617F ---
Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.. null. --- V617F ---
- The patient has a detectable JAK2 V617F mutation. --- V617F ---
HPO Nodes
HPO:Polycythemia
Genes 19
EPO CCND1 ACVRL1 GATA1 VHL EPAS1 EGLN1 FH SLC30A10 SLC30A10 CYB5R3 SH2B3 PKLR JAK2 JAK2 EPOR BPGM ENG VHL hr>Thrombocytosis
Genes 37
TTC37 RPSA MPL THPO HMGCL SKIV2L CD55 ACAT1 TBC1D24 THPO CALR SH2B3 PMM2 TTC37 MTHFD1 ADA2 JAK2 RUNX1 TET2 LMNA JAK2 JAK2 CALR IFNGR1 ELANE MPL RPS14 SF3B1 RPS19 HBB STING1 MPL BCR TET2 JAK2 ABL1 ZMPSTE24 hr>